As of the writing of this study, the list of commercially available biologic agents for psoriasis is constantly growing, including, but not limited to, inhibitors of tumor necrosis factor (TNF), interleukin (IL)-17 receptor, IL-17, IL-12/23, IL-23, phosphodiesterase, and Janus kinases. This evidence concerns the gene IL17A and psoriasis.